Our Mission

We're on a mission to unleash faster and more effective drug discovery. Led by experts in the fields of computational and synthetic biology and drug discovery, we are pioneering network biomedicine - combining high-throughput, massively parallel biological experimentation with high-throughput computation to empower better drug development and medicine.

Our Approach

Faced with these problems, our team asked a few questions:
What if instead of serial experimentation (“one by one”), we could do massively parallel experimentation (“all at once”)?
What if we had rich datasets on genetic interactions in specific biological (e.g. disease) contexts?
What if we could use these datasets to build cellular maps, which could be probed to build a predictive engine for drug discovery?

What We Do

Accelerating drug discovery: Engine has developed an extensively validated platform for drug discovery that provides orders-of-magnitude gains in speed, scalability, and cost.

Tackling a fundamental healthcare problem: We still don’t understand the critical biological drivers for specific disease contexts, and this prevents us from creating targeted therapies for patients in need.

Developing a systematic, scalable network biomedicine platform: Engine’s artificial intelligence and genetic perturbation platform allows researchers and drug developers to uncover the gene interactions and biological networks underlying diseases faster and more cost-effectively than conventionally, test therapies that specifically target these interactions, and make important analyses and predictions for precision medicine applications.

Building a world-class team supported by top investors: Our scientific leadership team sits at the forefront of systems and synthetic biology, genome engineering, and data science. Collectively we have founded over ten technology and biotech companies which have achieved commercial success and technological breakthroughs, and we are passionate about applying our entrepreneurial experiences to our mission at Engine. Our investors represent some of the world’s leading investors and domain experts in biotech and deep tech.